Table 4.
Subgroup results of PFS and heterogeneity test
| Variables | Analysis number | HR (95% CI) | Heterogeneity test | ||
| Q | P value | I2 (%) | |||
| Total PFS | 9 | 2.567 (1.562 to 4.219) | 18.10 | 0.021 | 55.6 |
| Region | |||||
| Asian | 1 | 0.421 (0.084 to 2.114) | 0.00 | ||
| Caucasian | 8 | 2.883 (1.830 to 4.544) | 12.99 | 0.072 | 46.1 |
| Sample size | |||||
| >100 | 5 | 2.559 (1.372 to 4.774) | 9.26 | 0.055 | 56.8 |
| ≤100 | 4 | 2.536 (0.943 to 6.818) | 8.75 | 0.033 | 65.7 |
| Follow-up (month) | |||||
| ≥60 | 6 | 2.153 (0.984 to 4.710) | 13.08 | 0.023 | 61.8 |
| <60 | 3 | 3.158 (1.774 to 5.623) | 3.56 | 0.169 | 43.8 |
| Stage | |||||
| All NMIBC | 3 | 4.673 (1.938 to 11.264) | 3.29 | 0.193 | 39.2 |
| Others | 6 | 2.044 (1.213 to 15.040) | 9.58 | 0.088 | 47.8 |
| Cut-off | |||||
| 15% | 1 | 2.800 (1.447 to 5.418) | 0.00 | ||
| Others | 8 | 2.515 (1.382 to 4.576) | 17.92 | 0.012 | 60.9 |
| Publication year | |||||
| ≥2012 | 5 | 1.685 (0.883 to 3.215) | 8.04 | 0.090 | 50.2 |
| <2012 | 4 | 4.176 (2.209 to 7.884) | 5.00 | 0.172 | 40.0 |
| Patient age (year) | |||||
| ≥70 | 2 | 2.519 (1.377 to 4.606) | 0.60 | 0.438 | 0.0 |
| <70 | 7 | 2.654 (1.381 to 5.100) | 17.40 | 0.008 | 65.5 |
| Multivariate/univariate | |||||
| Multivariate | 6 | 2.101 (1.070 to 1.121) | 13.83 | 0.031 | 63.8 |
| Univariate | 3 | 2.803 (1.652 to 7.856) | 3.38 | 0.001 | 40.8 |
NMIBC, non-muscle invasive bladder cancer; PFS, progression-free survival.